In recent years, GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have gained attention for their effectiveness in managing diabetes and supporting ...

President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the federal ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Dr. Michael Greger is famous for several books including “How Not to Die,” and for his website nutritionfacts.org. He ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing ...